Lunglife Ai Share Price (LLAI)

Something not right here. Are they making any money? One trick pony? It improves on current ways to diagnose but is it enough?

Extract from an article in today's Shares magazine by AJ Bell, on the role of AI in medicine:

AIM-quoted LungLife AI (LLAI:AIM) is a diagnostic company focused on the early detection of lung cancer.

The company is developing a test that pairs a simple blood draw with artificial intelligence to provide clinicians and patients the information they need to make informed decisions about the management of lung nodules and lung cancer.

In January 2024 the results of a clinical study demonstrated a strong PPV (positive predictive value) of 81% in discriminating cancerous lung nodules in patients with smaller nodules less than 15 millimetres.

These types of nodules present the greatest challenge for physicians in detecting cancers. Current standard of care generates a PPV of 60% which leads to material delays in diagnosis of deadly cancers.

Https://www.voxmarkets.co.uk/articles/lunglife-ai-unlocking-value-in-lung-cancer-diagnostics-1beb9f9/

Cash runway until mid 25..

Strengthens balance sheet ahead of working further towards commercial deals.

“The net proceeds of the Fundraising, along with the Company's existing cash resources, are expected to be utilised to establish the commercial proof of concept of the Company's LungLB® test”

You can still buy less than the fund raise..

Hopefully this will start to go north